Drug Development

Feliza Mirasol is the science editor for 

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Articles

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 2

Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 1 

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Investing in formulation strategies earlier on in development will maximize the chance of success.

The Earlier the Better for Formulation Strategies

Alternative drug delivery approaches are promising, but due to their complexity, they need to be sufficiently justified.

Taking an Alternative Approach to Drug Delivery

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Best practices help mitigate generic drug shortages.

Meeting Supply and Training Challenges 

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

SEDDS and SMEDDS improve solubility and permeability while expanding efficacy and applicability.

Lipids for Self-Emulsifying Drug Delivery Systems

Novavax has filed its COVID-19 vaccine for authorization in the UK and Australia. 

Novavax Files for Authorization of its COVID-19 Vaccine in the UK and Australia 

Crystec and Biosidus have joined forces to enhance the delivery and performance of biotherapeutics.

Crystec, Biosidus Collaborate on Enhanced Delivery and Performance of Biotherapeutics 

EMA's CHMP has approved two new manufacturing sites and a ready-to-use formulation of Comirnaty.

EMA Approves Two New Manufacturing Sites and a New Formulation for Comirnaty

EMA has started its evaluation of further expanded use of Comirnaty in children aged between five years and 11 years old.

Formulation and Drug Delivery